News Releases
DRI Capital Announces Expansion of Strategic Advisory Board with Appointment of Two New Members
Existing and newly appointed Board members bring extensive industry expertise, will help identify new growth opportunities as well as accelerate and diversify royalty deals TORONTO, Jan. 27, 2022 /CNW/ – DRI Capital Inc. (“DRI”), a pioneer and global leader in pharmaceutical royalty investing, today announced the expansion of its Strategic Advisory Board (“the Board”) with the appointment of two new
DRI Healthcare Trust Declares Special Distributions
DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI” or “the Trust”) today announced that its Board of Trustees has declared a special cash distribution in the amount of US$0.22 per trust unit….
DRI Healthcare Trust Comments on Extension of Review Period for pacritinib
DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI” or “the Trust”) today announced that it has been notified by CTI BioPharma Corp. (CTI) that the U.S. Food and Drug Administration (FDA) has…
DRI Healthcare Trust Reports Third Quarter 2021 Results and Announces Increase to Quarterly Distribution
– Continued strong performance of core royalty assets – – Demonstrated growth strategy execution through two transactions valued at up to $185 million – – Quarterly distribution doubled to…
DRI Healthcare Trust to Host Third Quarter Earnings Call and Webcast on November 9, 2021
DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI” or “the Trust”) announced today it will hold a conference call to discuss its 2021 third quarter financial results on Tuesday, November 9,…
DRI Healthcare Trust Announces US$200 Million Credit Facility
DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI” or “the Trust”) announced today that a subsidiary of the Trust has entered into a credit agreement with a syndicate of banks regarding US$200…
DRI Healthcare Trust Announces Acceptance by TSX of Normal Course Issuer Bid
DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI” or “the Trust”) announced today the acceptance by the Toronto Stock Exchange (the “TSX”) of the Trust’s Notice of Intention to make a normal…
DRI Healthcare Trust Announces Acquisition of Royalty on Oracea®
– Oracea® is the only branded oral prescription medication indicated for papulopustular rosacea – TORONTO, Sept. 30, 2021 /CNW/ – DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI” or “the Trust”
DRI Healthcare Trust to Host Conference Call to Discuss Transaction Announcement
DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI” or “the Trust”) announced today that it will be conducting a conference call to discuss the Trust’s previously announced debt and royalty…
CTI BioPharma and DRI Healthcare Trust Announce up to $135 Million Debt and Royalty Transaction
– Transaction to Fund Launch and Commercialization of Pacritinib in the United States This Year Pending FDA Approval, and Future Commercialization – SEATTLE and TORONTO, Aug. 25, 2021 /CNW/ -…
